The Medical Advisor

CancerDefeated.com - Prostate cancer kills about 28,000 every year… just in the United States. And each year, about 220,000 new cases are diagnosed. As things stand, one man out of every six will get prostate cancer during his lifetime. In my opinion, every man over the age of 50 should be thinking about his plan for dealing with this disease because so many of us will get it. Better to inform yourself about your options now, in a calm frame of mind, instead of waiting until you’re diagnosed – and fear sets in. But please be aware one of the most common treatments doctors recommend might not help – even though it’s been the medical standard for nearly seven decades. Worse yet, it could literally make you lose your mind! Here’s the full story. . . It’s hard to believe, but I still encounter even top-notch integrative doctors who insist androgen deprivation therapy is a good option for prostate cancer. If alternative doctors are saying this, you can bet that legions of conventional docto...

Abstract Background: Advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant forms, often develops resistance to standard androgen deprivation therapies, highlighting the need for novel adjunctive strategies. Repurposed antiparasitic agents such as fenbendazole and ivermectin have garnered attention for their potential anticancer properties, supported by preclinical studies demonstrating microtubule disruption, apoptosis induction, and metastasis inhibition. Methods: This compilation reviews 123 case reports from 2024–2026, sourced from peer-reviewed publications, social media platforms, and personal testimonials. Protocols typically involved fenbendazole (222–2000 mg/day) and ivermectin (1–2 mg/kg/day), often combined with adjuncts l...